^
Association details:
| Biomarker: | VEGFA elevation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma.
Published date:
05/25/2023
Excerpt:
Among patients with advanced nccRCC or sccRCC, a baseline high systemic inflammatory state and high circulating VEGF-A are associated with worse outcomes after treatment with atezolizumab and bevacizumab.
DOI:
10.1200/JCO.2023.41.16_suppl.4535
